ProKidney Corp. (NASDAQ:PROK) Insider Control Empresarial De Capital Buys 1,032,218 Shares

ProKidney Corp. (NASDAQ:PROK) insider Control Empresarial De Capital purchased 1,032,218 shares of the business’s stock in a transaction on Thursday, April 10th. The shares were bought at an average cost of $0.61 per share, for a total transaction of $629,652.98. Following the completion of the transaction, the insider now directly owns 72,592,325 shares in the company, valued at $44,281,318.25. This trade represents a 1.44 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link.

ProKidney Stock Up 1.2 %

ProKidney stock opened at $0.74 on Tuesday. The business’s 50-day moving average price is $1.08 and its 200 day moving average price is $1.53. The firm has a market cap of $216.60 million, a price-to-earnings ratio of -1.35 and a beta of 1.52. ProKidney Corp. has a 52 week low of $0.46 and a 52 week high of $4.44.

ProKidney (NASDAQ:PROK) last posted its earnings results on Monday, March 17th. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.03). The firm had revenue of $0.08 million for the quarter. Equities analysts expect that ProKidney Corp. will post -0.57 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. XTX Topco Ltd purchased a new position in ProKidney during the third quarter worth approximately $41,000. ProShare Advisors LLC grew its stake in ProKidney by 57.3% in the 4th quarter. ProShare Advisors LLC now owns 30,879 shares of the company’s stock valued at $52,000 after acquiring an additional 11,250 shares during the period. Sei Investments Co. purchased a new stake in ProKidney in the 4th quarter worth $69,000. The Manufacturers Life Insurance Company lifted its holdings in ProKidney by 54.6% during the third quarter. The Manufacturers Life Insurance Company now owns 37,981 shares of the company’s stock valued at $73,000 after purchasing an additional 13,415 shares in the last quarter. Finally, Susquehanna Fundamental Investments LLC acquired a new stake in shares of ProKidney in the fourth quarter valued at about $88,000. Institutional investors and hedge funds own 51.59% of the company’s stock.

ProKidney Company Profile

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.